- Nano cap Trovagene (TROV +2.9%) perks up on modestly higher volume on the news that the FDA has accepted its Investigational New Drug (IND) application seeking authorization to initiate clinical studies assessing PLK1 inhibitor PCM-075 for the treatment of acute myeloid leukemia (AML).
- First up will be a Phase 1b/2 open-label trial, first to identify the optimum dose and then to assess efficacy.
FDA accepts Trovagene's IND application for AML candidate PCM-075; shares ahead 3%
Recommended For You
About CRDF Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
CRDF | - | - |
Cardiff Oncology, Inc. |